Is agalsidase beta approved by regulators?

Yes. It was approved in the EU in 2001 and by the US FDA in 2003, marketed as Fabrazyme.

How is it administered?

As an intravenous infusion of 1 mg/kg once every 2 weeks in a clinical setting, with early infusions given slowly to reduce reactions.

Do patients develop antibodies to it?

Yes, most treated patients form anti-drug IgG antibodies. These can contribute to infusion reactions and, in some, reduce substrate clearance, so tolerability and response are monitored.

Does it treat brain involvement in Fabry disease?

Not directly. The infused enzyme does not cross the blood-brain barrier, so central nervous system manifestations such as stroke risk are not corrected by enzyme reaching the brain.

EMA-approvedaka Fabrazyme

Agalsidase beta — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Agalsidase beta (also known as Fabrazyme) is a peptide catalogued under Enzymes (Fabry). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Agalsidase beta?

Agalsidase beta (brand name Fabrazyme) is a recombinant human alpha-galactosidase A approved as enzyme replacement therapy for Fabry disease; it was approved by the EMA in 2001 and by the US FDA in 2003.

Its evidence base includes a pivotal randomised placebo-controlled trial, a randomised trial in advanced disease, and long-term extension and Fabry Registry data, giving a robust human evidence level.

It is a licensed biologic prescription medicine, not a peptide supplement, given under specialist care.

How does Agalsidase beta work?

Agalsidase beta carries mannose-6-phosphate residues that bind cell-surface receptors, delivering the enzyme to lysosomes where it hydrolyses accumulated globotriaosylceramide (GL-3/Gb3).

Clearing this glycosphingolipid from vascular endothelium, kidney, heart and other tissues aims to slow the progressive organ damage of Fabry disease.

What does the research say about Agalsidase beta?

In the pivotal randomised placebo-controlled trial, agalsidase beta cleared microvascular endothelial deposits of GL-3 in the kidney, heart and skin. ^[1]
In patients with advanced disease, agalsidase beta reduced the risk of a composite of renal, cardiac and cerebrovascular events versus placebo in a randomised trial. ^[2]
Fabry Registry data indicate earlier initiation of agalsidase beta is associated with greater clinical benefit over time. ^[5]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease — Eng CM et al., The New England Journal of Medicine 2001. (Randomised placebo-controlled trial (pivotal))
[2] Agalsidase-beta therapy for advanced Fabry disease: a randomized trial — Banikazemi M et al., Annals of Internal Medicine 2007. (Randomised controlled trial)
[3] Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease — Germain DP et al., Journal of the American Society of Nephrology 2007. (Long-term extension study)
[4] Long-term safety and efficacy of enzyme replacement therapy for Fabry disease — Wilcox WR et al., American Journal of Human Genetics 2004. (Open-label extension)
[5] Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry — Ortiz A et al., Journal of Medical Genetics 2016. (Registry cohort)
[6] Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease — Germain DP et al., Journal of Medical Genetics 2015. (Long-term cohort)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical practice agalsidase beta is administered as an intravenous infusion of 1 mg/kg once every 2 weeks, with the first infusions given slowly to manage reactions.

This is context only, not a dosing recommendation; therapy is prescribed and monitored by a specialist.

Side effects & safety profile

Infusion-associated reactions (rigors, fever, chills, dyspnoea) are common, particularly early in treatment, and may require premedication, slower infusion rates or dose adjustment.

The majority of treated patients develop anti-agalsidase beta IgG antibodies, which in some cases attenuate GL-3 clearance and are linked to infusion reactions, so antibody status and tolerability are monitored.

As an intravenous enzyme it does not cross the blood-brain barrier, so the cerebrovascular and neuropathic pain components mediated centrally are not directly corrected by enzyme delivery to the brain.

Stacking & combinations

It is a condition-specific enzyme replacement and is not intended to be combined with research peptides, supplements or other unapproved agents.

Finding Agalsidase beta vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is enzyme replacement therapy for Fabry disease, supplying the deficient enzyme alpha-galactosidase A to clear the fatty substance GL-3 that accumulates in blood vessels and organs.

References

[1] Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease — Eng CM et al., The New England Journal of Medicine 2001. PMID: 11439963. View sourceStudy: Randomised placebo-controlled trial (pivotal)Agalsidase beta cleared microvascular endothelial GL-3 deposits in kidney, heart and skin compared with placebo.
[2] Agalsidase-beta therapy for advanced Fabry disease: a randomized trial — Banikazemi M et al., Annals of Internal Medicine 2007. PMID: 17179052. View sourceStudy: Randomised controlled trialIn advanced Fabry disease, agalsidase beta delayed the composite endpoint of renal, cardiac and cerebrovascular events relative to placebo.
[3] Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease — Germain DP et al., Journal of the American Society of Nephrology 2007. PMID: 17409312. View sourceStudy: Long-term extension studyContinued agalsidase beta was associated with sustained stabilisation of renal function over 54 months in most patients.
[4] Long-term safety and efficacy of enzyme replacement therapy for Fabry disease — Wilcox WR et al., American Journal of Human Genetics 2004. PMID: 15154115. View sourceStudy: Open-label extensionSustained GL-3 clearance and an acceptable long-term safety profile were shown over extended agalsidase beta treatment.
[5] Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry — Ortiz A et al., Journal of Medical Genetics 2016. PMID: 26993266. View sourceStudy: Registry cohortRegistry analysis suggested clinical benefit accrues over time and supports earlier initiation of agalsidase beta.
[6] Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease — Germain DP et al., Journal of Medical Genetics 2015. PMID: 25795794. View sourceStudy: Long-term cohortMost patients who started agalsidase beta with limited baseline damage remained free of major clinical events over 10 years.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.